Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis
-
- Giulia Marzocchi
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
-
- Fausto Castagnetti
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
-
- Simona Luatti
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
-
- Carmen Baldazzi
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
-
- Monica Stacchini
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
-
- Gabriele Gugliotta
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
-
- Marilina Amabile
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
-
- Giorgina Specchia
- Hematology, University of Bari, Italy;
-
- Mario Sessarego
- Department of Internal Medicine, University of Genova, Genova, Italy;
-
- Ursula Giussani
- Cytogenetics Unit, Bergamo, Italy;
-
- Laura Valori
- Cytogenetics Unit, Treviso, Italy;
-
- Giancarlo Discepoli
- Centre of Medical Genetic and Prenatal Diagnosis, Ancona, Italy;
-
- Anna Montaldi
- Department of Hematology, Vicenza, Italy;
-
- Alessandra Santoro
- Department of Clinical and Biotechnological Research, A.O.U. “Cervello,” Palermo, Italy;
-
- Laura Bonaldi
- Molecolar Oncology and Cytodiagnostic Unit, University of Padova, Padova, Italy;
-
- Giovanni Giudici
- Research Center “Tettamanti,” Monza, Italy;
-
- Anna Maria Cianciulli
- Clinical Pathology Department “Regina Elena Institute,” Rome, Italy;
-
- Francesca Giacobbi
- Hematology University of Modena, Modena, Italy;
-
- Francesca Palandri
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
-
- Fabrizio Pane
- Department of Biochemistry and Medical Biotechnology, “Federico II” University, Napoli, Italy; and
-
- Giuseppe Saglio
- Department of Clinical and Biological Sciences, University of Torino, Orbassano, Italy
-
- Giovanni Martinelli
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
-
- Michele Baccarani
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
-
- Gianantonio Rosti
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
-
- Nicoletta Testoni
- Department of Hematology and Oncology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;
説明
<jats:title>Abstract</jats:title> <jats:p>Variant Philadelphia (Ph) chromosome translocations have been reported in 5%-10% of patients with newly diagnosed chronic myeloid leukemia (CML). Variant translocations may involve one or more chromosomes in addition to 9 and 22, and can be generated by 2 different mechanisms, 1-step and 2-step rearrangements, as revealed by fluorescence in situ hybridization. The prognostic significance of the occurrence of variant translocations has been discussed in previous studies. The European LeukemiaNet recommendations do not provide a “warning” for patients with variant translocations, but there is limited information about their outcome after therapy with tyrosine kinase inhibitors. To identify the role of variant translocations in early chronic phase (CP) CML patients treated with imatinib mesylate, we performed an analysis in a large series of 559 patients enrolled in 3 prospective imatinib trials of the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on CML. Variant translocations occurred in 30 patients (5%). Our data show that the presence of variant translocations has no impact on the cytogenetic and molecular response or on outcome, regardless of the involvement of different mechanisms, the number of involved chromosomes, or the presence of deletions. Therefore, we suggest that patients with variant translocations do not constitute a “warning” category in the imatinib era. This study is registered at www.clinicaltrials.gov as NCT00514488 and NCT00510926.</jats:p>
収録刊行物
-
- Blood
-
Blood 117 (25), 6793-6800, 2011-06-23
American Society of Hematology